BioArctic and Uppsala University are working on new antibody technology

| By | Drug Development, R&D

BioArctic AB, a Swedish research based biopharma company focusing on disease modifying treatments and reliable biomarkers and diagnostics for neurodegenerative diseases, announced that the company has signed an extended research collaboration agreement with Uppsala University, Department of Pharmaceutical Biosciences.

Uppsala University, the oldest university in Sweden and all of the Nordic countries, was founded in 1477 and is ranked as one of the world’s 100 best universities.

The extended research collaboration concerns technologies for increased passage across the blood-brain barrier and BioArctic will contribute financial support for a three year post-doc research position.

The blood-brain barrier is a membrane that controls the exchange of substances between the blood and the brain. The barrier protects the brain from toxins and pathogens, but it also makes it more difficult to deliver therapeutic agents to the brain. Under an earlier collaboration with Uppsala University, BioArctic develops a technology that facilitates the passage of antibodies across the blood-brain barrier. This project is in research phase.

The new extended research collaboration aims to develop innovative technologies to increase the passage of antibodies also into nerve cells. This can be of great value for the diagnosis and treatment of neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease.

SOURCE: bioarctic
GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.